VERACYTE, INC. (a Delaware corporation) 5,000,000 Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • July 26th, 2018 • Veracyte, Inc. • Services-medical laboratories • New York
VERACYTE, INC. Shares of Common Stock (par value $0.001 per share) Controlled Equity OfferingSM Sales AgreementSales Agreement • June 24th, 2015 • Veracyte, Inc. • Services-medical laboratories • New York
Veracyte, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cantor Fitzgerald & Co. (the “Agent”), as follows:
Shares VERACYTE, INC. COMMON STOCK, PAR VALUE $0.001 PER SHARE UNDERWRITING AGREEMENTUnderwriting Agreement • October 25th, 2013 • Veracyte, Inc. • Services-medical laboratories • New York
The undersigned understands that Morgan Stanley & Co. LLC (“Morgan Stanley”) and Leerink Swann LLC (“Leerink”), together as representatives of the several Underwriters (as defined below), propose to enter into an Underwriting Agreement (the “Underwriting Agreement”) with Veracyte, Inc., a Delaware corporation (the “Company”), providing for the public offering (the “Public Offering”) by the several Underwriters, including Morgan Stanley and Leerink (the “Underwriters”), of shares (the “Shares”) of common stock, par value $0.001 per share, of the Company (the “Common Stock”).
VERACYTE, INC. (a Delaware corporation) 5,000,000 Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • November 2nd, 2016 • Veracyte, Inc. • Services-medical laboratories • New York
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • April 24th, 2015 • Veracyte, Inc. • Services-medical laboratories • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of April 22, 2015, by and among Veracyte, Inc, a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”).
VERACYTE, INC. CHANGE OF CONTROL AND SEVERANCE AGREEMENTChange of Control and Severance Agreement • February 29th, 2024 • Veracyte, Inc. • Services-medical laboratories • California
This Change of Control and Severance Agreement (the “Agreement”) is made and entered into by and between John Leite (“Executive”) and Veracyte, Inc., a Delaware corporation (the “Company”), effective as of September 1, 2023 (the “Effective Date”).
VERACYTE, INC. COMMON STOCK, PAR VALUE $0.001 PER SHARE UNDERWRITING AGREEMENTUnderwriting Agreement • February 5th, 2021 • Veracyte, Inc. • Services-medical laboratories • New York
ContractWarrant Agreement • September 20th, 2013 • Veracyte, Inc. • Services-medical laboratories • California
THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 5.3 AND 5.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR IN FORM AND SUBSTANCE SATISFACTORY TO THE COMPANY, SUCH OFFER, SALE, PLEDGE OR OTHER TRANSFER IS EXEMPT FROM SUCH REGISTRATION.
LOAN AND SECURITY AGREEMENTLoan and Security Agreement • February 27th, 2018 • Veracyte, Inc. • Services-medical laboratories • Delaware
THIS LOAN AND SECURITY AGREEMENT (this “Agreement”) dated as of November 3, 2017 (the “Effective Date”) between SILICON VALLEY BANK, a California corporation (“Bank”), and VERACYTE, INC., a Delaware corporation (“Borrower”), provides the terms on which Bank shall lend to Borrower and Borrower shall repay Bank. The parties agree as follows:
AGREEMENT AND PLAN OF MERGERMerger Agreement • May 10th, 2021 • Veracyte, Inc. • Services-medical laboratories • Delaware
This Agreement and Plan of Merger (this “Agreement”) is made and entered into as of February 2, 2021 (the “Agreement Date”), by and among Veracyte, Inc., a Delaware corporation (“Acquirer”), Delight Merger Sub I, a Delaware corporation and wholly owned subsidiary of Acquirer (“Merger Sub I”), Delight Merger Sub II, LLC, a Delaware limited liability company and a direct, wholly owned subsidiary of Acquirer (“Merger Sub II” and together with Merger Sub I, the “Merger Subs”), Decipher Biosciences, Inc., a Delaware corporation (the “Company”), and Fortis Advisors LLC, a Delaware limited liability company, as the stockholders’ agent (the “Stockholders’ Agent”). Certain other capitalized terms used herein are defined in Exhibit A.
LOAN AND SECURITY AGREEMENTLoan and Security Agreement • August 13th, 2013 • Veracyte, Inc. • Services-medical laboratories • Delaware
THIS LOAN AND SECURITY AGREEMENT (this “Agreement”) dated as of June 26, 2013 (the “Effective Date”) between SILICON VALLEY BANK, a California corporation (“Bank”), and VERACYTE, INC., a Delaware corporation (“Borrower”), provides the terms on which Bank shall lend to Borrower and Borrower shall repay Bank. The parties agree as follows:
PLEDGE AGREEMENTPledge Agreement • May 5th, 2016 • Veracyte, Inc. • Services-medical laboratories
THIS PLEDGE AGREEMENT dated as of March 30, 2016 (as amended, modified, restated or supplemented from time to time, this “Pledge Agreement”) is by and among the parties identified as “Pledgors” on the signature pages hereto and such other parties as may become Pledgors hereunder after the date hereof (individually a “Pledgor”, and collectively, the “Pledgors”) and Visium Healthcare Partners, LP, as administrative agent (in such capacity, the “Administrative Agent”) for the Secured Parties (defined below).
SECURITY AGREEMENTSecurity Agreement • May 5th, 2016 • Veracyte, Inc. • Services-medical laboratories
THIS SECURITY AGREEMENT dated as of March 30, 2016 (as amended, modified, restated or supplemented from time to time, this “Security Agreement”) is by and among the parties identified as “Grantors” on the signature pages hereto and such other parties as may become Grantors hereunder after the date hereof (individually a “Grantor”, and collectively the “Grantors”) and Visium Healthcare Partners, LP, as administrative agent (in such capacity, the “Administrative Agent”) for the Secured Parties (defined below).
AMENDED AND RESTATED PATHOLOGY SERVICES AGREEMENTPathology Services Agreement • February 27th, 2018 • Veracyte, Inc. • Services-medical laboratories • Texas
THIS AMENDED AND RESTATED PATHOLOGY SERVICES AGREEMENT (“Agreement”) is made this 16th day of October, 2017 (the “Effective Date”), by and among VERACYTE, INC., a Delaware corporation (“Veracyte”), and THYROID CYTOPATHOLOGY PARTNERS, P.A., a Texas professional association (“Pathologists”). Veracyte and Pathologists are sometimes referred to in this Agreement as a “Party” or, collectively, as the “Parties.”
LEASE AGREEMENTLease Agreement • September 20th, 2013 • Veracyte, Inc. • Services-medical laboratories
THIS LEASE AGREEMENT (this “Lease”) is made as of this 10 day of February, 2010 (the “Lease Date”), between ARE-SAN FRANCISCO NO. 17, LLC, a Delaware limited liability company (“Landlord”), and VERACYTE, INC., a Delaware corporation (“Tenant”).
LEASE AGREEMENT BETWEEN RIATA HOLDINGS, L.P., AS LANDLORD, AND VERACYTE, INC., AS TENANT DATED NOVEMBER 28, 2012 RIATA CORPORATE PARK 12357 A RIATA TRACE PARKWAY, BUILDING 5 AUSTIN, TEXAS 78727Lease Agreement • September 20th, 2013 • Veracyte, Inc. • Services-medical laboratories • Texas
This Lease Agreement (this “Lease”) is entered into as of the Lease Date between Landlord and Tenant (as each such term is defined in the Basic Lease Information).
EX-U.S. CO-PROMOTION AGREEMENTCo-Promotion Agreement • March 25th, 2015 • Veracyte, Inc. • Services-medical laboratories • New York
Genzyme Corporation, with offices located at 500 Kendall Street, Cambridge, Massachusetts 02142 (hereinafter referred to as “Genzyme”)
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • April 24th, 2015 • Veracyte, Inc. • Services-medical laboratories
This Registration Rights Agreement (this “Agreement”) is made and entered into as of April 22, 2015, by and among Veracyte, Inc., a Delaware corporation (the “Company”), and the several purchasers signatory hereto (each a “Purchaser” and collectively, the “Purchasers”).
VERACYTE, INC. AMENDMENT TO BONNIE ANDERSON EMPLOYMENT AGREEMENTAmendment to Employment Agreement • September 20th, 2013 • Veracyte, Inc. • Services-medical laboratories • California
This Amendment to the Bonnie Anderson Employment Agreement (the “Amendment’’) is made as of December [22], 2008, by and between Veracyte, Inc. (formerly known as Calderome, Inc.) (the “Company”), and Bonnie Anderson (the “Executive”).
VERACYTE, INC. 2013 STOCK INCENTIVE PLAN (Adopted by the Board of Directors on October 2, 2013)2013 Stock Incentive Plan • October 7th, 2013 • Veracyte, Inc. • Services-medical laboratories
FIRST AMENDMENT TO PATHOLOGY SERVICES AGREEMENTPathology Services Agreement • September 20th, 2013 • Veracyte, Inc. • Services-medical laboratories
THIS FIRST AMENDMENT TO PATHOLOGY SERVICES AGREEMENT (the “Amendment”) is made and entered into as of December 19, 2012, by and between VERACYTE, INC., a California corporation (“Veracyte”) and THYROID CYTOLOGY PARTNERS, P.A., a Texas professional association (“Pathologists”) with respect to the following:
VERACYTE, INC. AMENDMENT NO. 2 TO BONNIE ANDERSON EMPLOYMENT AGREEMENTEmployment Agreement • September 20th, 2013 • Veracyte, Inc. • Services-medical laboratories • California
This Amendment No. 2 to the Bonnie Anderson Employment Agreement (the “Amendment”) is effective as of March 11, 2009, by and between Veracyte, Inc. (formerly known as Calderome, Inc.) (the “Company”), and Bonnie Anderson (the “Executive”).
VERACYTE, INC. AMENDMENT TO SECOND AMENDED AND RESTATED INVESTOR RIGHTS’ AGREEMENTInvestor Rights Agreement • September 20th, 2013 • Veracyte, Inc. • Services-medical laboratories
This Amendment to Second Amended and Restated Investors’ Rights Agreement (this “Amendment”) is entered and effective as of June 14, 2013, by and among Veracyte, Inc., a Delaware corporation (the “Company”), and the undersigned stockholders of the Company’s issued and outstanding Preferred Stock (the “Stockholders”).
CALDEROME, INC. EMPLOYMENT AGREEMENTEmployment Agreement • September 20th, 2013 • Veracyte, Inc. • Services-medical laboratories • California
This Agreement is entered into as of February 15, 2008, (the “Effective Date”) by and between Calderome, Inc., a Delaware corporation (the “Company”), and Bonnie Anderson (“Executive”).
LOAN AND SECURITY AGREEMENTLoan Agreement • September 20th, 2013 • Veracyte, Inc. • Services-medical laboratories • Delaware
THIS LOAN AND SECURITY AGREEMENT (this “Agreement”) dated as of June 26, 2013 (the “Effective Date”) between SILICON VALLEY BANK, a California corporation (“Bank”), and VERACYTE, INC., a Delaware corporation (“Borrower”), provides the terms on which Bank shall lend to Borrower and Borrower shall repay Bank. The parties agree as follows:
VERACYTE, INC. SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT November 6, 2012Investors’ Rights Agreement • September 20th, 2013 • Veracyte, Inc. • Services-medical laboratories • Delaware
This Second Amended and Restated Investors’ Rights Agreement (the “Agreement”) is entered into as of November 6, 2012, by and among Veracyte, Inc., a Delaware corporation (the “Company”) and the investors listed on Exhibit A hereto, referred to hereinafter as the “Investors” and each individually as an “Investor.”
FIRST AMENDMENT TO LEASE AGREEMENTLease Agreement • September 20th, 2013 • Veracyte, Inc. • Services-medical laboratories
THIS FIRST AMENDMENT TO LEASE AGREEMENT (this “First Amendment”) is made and entered into as of July 11, 2012, by and between ARE-SAN FRANCISCO NO. 17, LLC, a Delaware limited liability company (“Landlord”), and VERACYTE, INC., a Delaware corporation (“Tenant”).
April 9, 2013Co-Promotion Agreement • September 20th, 2013 • Veracyte, Inc. • Services-medical laboratories
This letter (the “Amendment”), effective as of the date first indicated above (the “Amendment Date”), amends that certain Co-Promotion Agreement (the “CoPromote”) dated as of January 18, 2012 by and between Genzyme Corporation (“Genzyme”) and Veracyte, Inc. (“Veracyte”) in accordance with Section 12.11 thereto. All capitalized terms used but not otherwise defined herein shall have the respective meanings ascribed to them in the CoPromote.
LICENSE AND ASSET PURCHASE AGREEMENT BY AND BETWEEN VERACYTE, INC. AND NANOSTRING TECHNOLOGIES, INC. Dated as of December 3, 2019License and Asset Purchase Agreement • December 3rd, 2019 • Veracyte, Inc. • Services-medical laboratories • Delaware
This LICENSE AND ASSET PURCHASE AGREEMENT, dated as of December 3, 2019 (this “Agreement”), is by and between Veracyte, Inc., a Delaware corporation (“Veracyte”) and NanoString Technologies, Inc., a Delaware corporation (“NanoString”). NanoString and Veracyte are each referred to as a “Party” and collectively as the “Parties”.
APPROVAL OF VERACYTE, INC.Pathology Services Agreement • September 20th, 2013 • Veracyte, Inc. • Services-medical laboratories
Reference is made to that certain Pathology Services Agreement (the “Contract”) dated November 12, 2010 by and among Veracyte, Inc. (“Veracyte”) and Brazos Valley Pathology, P.A. (“BVPPA”). As of May 18, 2011, Veracyte hereby consents to the assignment of the Contract from BVPPA to Thyroid Cytopathology Partners, P.A. (“TCP”) as provided in that certain Assignment of Contract dated Dec 2, 2010.
INDEMNIFICATION AGREEMENTIndemnification Agreement • October 7th, 2013 • Veracyte, Inc. • Services-medical laboratories • Delaware
This Indemnification Agreement (the “Agreement”), is dated as of , 20 between Veracyte, Inc., a Delaware corporation (the “Corporation”), and (“Indemnitee”).
FIRST AMENDMENT TO LEASE AGREEMENTLease Agreement • March 20th, 2014 • Veracyte, Inc. • Services-medical laboratories • Texas
THIS FIRST AMENDMENT TO LEASE (this “Amendment”) is made and entered into as of January 7, 2014, by and between RIATA HOLDINGS, L.P., Delaware limited partnership doing business in Texas as Riata Austin Holdings, L.P. (“Landlord”), and VERACYTE, INC., a Delaware corporation (“Tenant”).
CONSENT AND SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENTLoan and Security Agreement • November 24th, 2015 • Veracyte, Inc. • Services-medical laboratories • California
THIS CONSENT AND SECOND AMENDMENT to Loan and Security Agreement (this “Amendment”) is entered into as of November 24, 2015, by and between SILICON VALLEY BANK (“Bank”) and VERACYTE, INC., a Delaware corporation (“Borrower”).
FIRST AMENDMENT TO CREDIT AGREEMENTCredit Agreement • March 1st, 2017 • Veracyte, Inc. • Services-medical laboratories • New York
THIS FIRST AMENDMENT TO CREDIT AGREEMENT (this “Agreement”) dated as of December 14, 2016 (the “Effective Date”) is entered into among Veracyte, Inc., a Delaware corporation (the “Borrower”), the Guarantors, the Lenders party hereto and VISIUM HEALTHCARE PARTNERS, LP, a Delaware limited partnership, as Administrative Agent. All capitalized terms used herein and not otherwise defined herein shall have the meanings given to such terms in the Credit Agreement (as defined below).
May 28, 2021 Ms. Bonnie Anderson Delivered by hand or via email Dear Bonnie:Employment Agreement • July 29th, 2021 • Veracyte, Inc. • Services-medical laboratories • California
Veracyte, Inc. (the “Company”) is pleased to offer you this letter agreement (this “Agreement”) setting forth the terms and conditions of your transition to, and employment as, Executive Chairman of the Company.
